Acalabrutinib and Apalutamide: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong CYP3A induction can reduce exposure to the anticancer medicine.
Clinical significance and safety
Acalabrutinib with Apalutamide can reduce the effectiveness of the affected anticancer treatment. The product information recommends avoiding strong CYP3A inducers where possible and considering an alternative with less inducing activity. The oncology team should decide whether a change is needed; do not stop or adjust either prescribed medicine yourself.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.